Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$602 Mln
P/E Ratio
--
P/B Ratio
1.07
Industry P/E
--
Debt to Equity
0.02
ROE
-0.33 %
ROCE
-32.24 %
Div. Yield
0 %
Book Value
7.8
EPS
-2.76
CFO
$-222.69 Mln
EBITDA
$-1,089.91 Mln
Net Profit
$-1,076.20 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Arvinas (ARVN)
| -52.06 | 5.03 | -48.94 | -72.97 | -47.19 | -29.37 | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Arvinas (ARVN)
| -53.13 | 20.32 | -58.35 | -3.29 | 106.69 | 219.77 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 9,808.03 | 20.22 | 23.13 | |
| 295.46 | 8,956.09 | 22.08 | 58.42 | |
| 26.65 | 9,559.25 | -- | -28.77 | |
| 105.01 | 10,030.35 | 30.81 | 14.16 |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein... degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. Address: 5 Science Park, New Haven, CT, United States, 06511 Read more
Chairperson, CEO & President
Dr. John G. Houston Ph.D.
Chairperson, CEO & President
Dr. John G. Houston Ph.D.
Headquarters
New Haven, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Arvinas Inc (ARVN) stood at $ 1,091 Mln as on 31-Dec-24
The share price of Arvinas Inc (ARVN) is $9.19 (NASDAQ) as of 24-Apr-2025 10:44 EDT. Arvinas Inc (ARVN) has given a return of -47.19% in the last 3 years.
Arvinas Inc (ARVN) has a market capitalisation of $ 602 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Arvinas Inc (ARVN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Arvinas Inc (ARVN) and enter the required number of quantities and click on buy to purchase the shares of Arvinas Inc (ARVN).
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. Address: 5 Science Park, New Haven, CT, United States, 06511
The CEO & director of Dr. John G. Houston Ph.D.. is Arvinas Inc (ARVN), and CFO & Sr. VP is Dr. John G. Houston Ph.D..
There is no promoter pledging in Arvinas Inc (ARVN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Arvinas Inc. (ARVN) | Ratios |
|---|---|
|
Return on equity(%)
|
-32.56
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-75.51
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Arvinas Inc (ARVN) was $0 Mln.
$0.12
(
